Navigation Links
Leading Indian CRO 'Max Neeman International' Expands in Response to Positive Biosimilars Market in India
Date:12/5/2011

RESEARCH TRIANGLE PARK, N.C., Dec. 5, 2011 /PRNewswire/ -- A dedicated and experienced Max Neeman team has been set-up to conduct Biosimilar studies for evaluation and efficacy of products. The company expanded into this arena because India has demonstrated the greatest acceptance of Biosimilars reflected by over 50 biopharmaceutical brands getting marketing approval.  CEO, Dr. Ajoy Kumar firmly believes in a responsive, knowledge-based organization to meet client's needs.

(Logo: http://photos.prnewswire.com/prnh/20110105/CL25129LOGO)

The Indian Biosimilars market in 2008 was estimated to be worth approximately $200 million by Universal Consulting [India-based market research firm].  This is forecasted to reach $580 million by 2012 due to two key factors:  relative cost advantage of Biosimilars development versus competitors elsewhere and lower regulatory requirements for establishing bioequivalence [which also helps to keep development costs low].  Currently the manufacture and marketing of Biosimilars in India is governed by the Environment Protection Act of 1970 and the Drugs and Cosmetic Act. 

About Max Neeman International
Max Neeman International is a leading Indian CRO. Our specialty is that we offer services for the successful conduct of Phase II-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is also an ISO 9001:2008 & ISO 27001:2005 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in 31 cities with 6 regional offices.   For more information, please contact Donald Swankie, Vice President Business Development at +1.919.424.3345 / donald.swankie@neeman-medical.com or visit www.neeman-medical.com.


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Introduces Industry-Leading ICD and CRT-D Device Warranties
2. Leading Executives Once Again Meet at GDS International’s Next Generation Pharmaceutical Manufacturing Europe Summit to Discuss Key Objectives For The Industry
3. RealTime Medical to Feature Industry-Leading Cross-Platform, Automated Shared Workflow and Dynamic Workflow Assignment Software at RSNA 2011
4. Leading Chemical Weapons Preparedness Companies Announce Partnership to Deploy Break-through Diagnostic Test Internationally
5. PAREXEL Advances Early Phase CNS Research Capabilities With Leading Medical Imaging Technology
6. Qmed, the Leading Global MedTech Industry Resource Announces New Regulatory Tool to Streamline and Simplify the Regulatory and Product Development Process
7. United Spinal Secures Leading Public Policy and Durable Medical Equipment Specialist: Alex Bennewith is New Director of Government Relations
8. Leading Health Organizations and Patient Groups Call for 20 Percent Reduction in Fractures by 2020
9. Patients at Risk for Hepatitis B Are Not Adequately Screened Before Receiving Chemotherapy Leading to the Preventable Reactivation of Hepatitis B Infection
10. The Future of GPCRs in Drug Discovery: Novel technologies, leading companies, and opportunities for target expansion
11. Hypertronics Partners with UBM Canon, the Leading Global Medical Device Industry Source, to Co-Host Strategies for Avoiding Device Failure Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges the ... how his administration could impact the employee benefits industry. James Slotnick, AVP, Government ... likely to make it through Congress. His discussion will focus on the current ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who ... achieves results in a fraction of the time as traditional braces – Wilckodontics®. ... Dental Specialists, now offers this revolutionary treatment with or without a referral. ...
(Date:4/25/2017)... Minneapolis MN (PRWEB) , ... April 25, 2017 , ... ... patients and recreational users to dispensaries and head shops –can’t help but be heartened ... loathing for the tell-tale cannabis odor aptly described as “skunk smell.” At last ...
(Date:4/25/2017)... Hollywood, Fl (PRWEB) , ... April 25, 2017 , ... ... than Memorial Regional Hospital, according to a special report in the May issue of ... Hospital its highest quality ranking for results achieved during and after coronary bypass ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG CNS ... Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national conference. ... pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit for ...
Breaking Medicine News(10 mins):